



Free Daily Biotech Industry Newsletter Get the latest on Biotech & Pharma Deals, Clinical Trials, FDA Decisions, and Key Regulatory Issues sent straight to your Inbox. Join over 150,000 biotech professionals who subscribe to *FierceBiotech* for FREE!
[Click here](#) to see a sample.

We never sell or give away your contact information. Our readers trust comes first.

EMAIL ADDRESS

SIGN ME UP

Topics: Regulatory

Pfizer, BMS win blockbuster FDA approval for Eliquis

December 28, 2012 | By Ryan McBride

SHARE

The FDA saved one of its biggest approvals of the year until the end of 2012. Eliquis, the clot buster from Bristol-Myers Squibb (\$BMY) and Pfizer (\$PFE), garnered the agency's stamp for use in certain patients with atrial fibrillation.



Bristol and Pfizer—which have suffered from generic competition to the big-selling meds Plavix and Lipitor, respectively—have now won approval for the most lucrative use of the drug in the world's top healthcare market. The FDA sanctioned the bloodthinner for reducing risk of stroke and blood clots in patients with non-valvular atrial fibrillation, saying that the drug shouldn't be used in patients with artificial heart valves or defective heart valves.

Atrial fibrillation (AF), a common irregular heart beat, afflicts more than 5.8 million Americans, according to the Bristol-Myers, and the ailment spikes their risk of stroke. Last year Pfizer and Bristol revealed that in a 18,201-patient study comparing Eliquis or apixaban to decades-old warfarin, the new clot buster lowered stroke risk by 21%, major bleeding by 31% and mortality by 11%.

TOOLS



Comment



Print



Contact Author



Reprint



[Webinar] Special Considerations for Managing Immuno-oncology Studies - A New Paradigm

DATE: WEDNESDAY, MARCH 9 | 11AM ET / 8AM PT

Immuno-Oncology Webinar: We are in a new era for researching cancer treatments. Join Medpace medical and operations experts as they discuss the unique considerations for managing immuno-oncology studies as well as insights into best practices. Reserve Your Spot Today!

Sign up for our FREE newsletter for more news like this sent to your inbox

"Blood clots in the heart can cause a disabling stroke if the clots travel to the brain," said Dr. Norman Stockbridge, director of the Division of Cardiovascular and Renal Products in the FDA's Center for Drug Evaluation and Research, in a statement.

Bristol and Pfizer have a potential mega-blockbuster product on their hands, with analysts estimating peak sales of more than \$5 billion. The drug faces competition from similar drugs such as Xarelto from Johnson & Johnson (\$JNJ) and Bayer and the bloodthinner Pradaxa from Boehringer Ingelheim. Yet some experts, including those cited by Leerink Swann, believe that Eliquis is the top new warfarin replacement.

Regulators in the European Union, Canada and Japan approved Eliquis before the

JOIN 150,000+ INSIDERS SIGN UP FOR OUR NEWSLETTER

FierceBiotech is the drug development industry's news monitor, covering biopharma deals, clinical trials, FDA decisions, and more. Subscribe to our free daily email and join the largest, most influential biotechnology news audience in the world. Sign up today!

EMAIL ADDRESS

SIGN ME UP

POPULAR STORIES

MOST READ

MOST SHARED

AstraZeneca's cancer checkpoint combo looks promising in small lung cancer study

Baxalta partner CTI plunges after FDA slaps partial hold on PhIII myelofibrosis drug

Hit with a storm of protest, LifeSci Advisors apologizes for its J.P. Morgan party

UPDATED: A patient in Akashi's suspended Duchenne MD trial dies

Biogen joins a GSK-led data-sharing project to make R&D more efficient

THE LIBRARY: WEBINAR

Life Sciences and Mobile Apps



| MARCH 17 | 1PM ET / 10AM PT | SPONSORED BY: APIAN

This webinar will examine app strategies in the life sciences industry and how they're changing in the wake of new regulatory requirements. Register Now!

MORE ITEMS

LATEST COMMENTARY

Martin Shkreli takes the 5th, then turns to Twitter to blast 'imbeciles'

Let this letter be a shot across the bow to the entire industry

requesting more information on data management and verification from the major Phase III study of more than 18,000 patients known as "Aristotle." Yet today's FDA approval comes almost three months before its March 17, 2013, PDUFA date.

- here's the release
- see *the Wall Street Journal's* article (sub. req.)
- check out *Bloomberg's* report
- and the item from *Reuters*

Special Report: Eliquis - Blockbuster buzz: 15 top therapies in late-stage development | **Slideshow:** FDA Approvals of 2012

Related Articles:

- Japan OKs warfarin alternative Eliquis from BMS, Pfizer
- Pfizer, Bristol-Myers win landmark European approval for Eliquis
- Setbacks tarnish Bristol-Myers' 'string of pearls'
- Pfizer and Bristol's Eliquis marches closer to FDA decision

Kochenderfer: 'I think the main focus of the CAR field will be autologous cells...'

UPDATED: Hedge fund's attack on troubled Zafgen draws blood

Who are the most influential people in biopharma today?

EVENTS

BioBasics: Biotech for the Non-Scientist Course | March 3-4, 2016 — Washington DC — Sponsored By: FierceBiotech & Venable

Lyophilization USA | 27th & 28th April 2016 Renaissance Woodbridge Hotel — Iselin, New Jersey, USA

Drug Development Immersion Course | May 17-18, 2016 — New York City, NY — Sponsored By: FierceBiotech & Venable

[MORE EVENTS](#)

Filed Under Bristol-Myers Squibb, Eliquis, FDA approval, Pfizer

COMMENTS

0 Comments FierceBiotech

Sort by Best

Be the first to comment.

ALSO ON FIERCEBIOTECH

[WHAT'S THIS?](#)

French drug trial disaster leaves patient dead amid a slew of ...
 2 comments · 21 days ago

Carlos N Velez/Lacerta Bio — I take issue with your use of the word "botched." This suggests that BIAL or someone made ...

Merck bets up to \$515M on an epigenetic project for cancer and ...
 1 comment · 12 days ago

mlerman — Summing up my work on cancer 1. To prevent cancer daily use a dose of aromatic sulfonamide ...

'Let this letter be a shot across the bow to the entire industry'
 14 comments · 7 days ago

Robbie — Get over it for God's sake. Remind me not hire those two inept people.

GlaxoSmithKline bails on Basilea's eczema drug, nixing a \$72M payout
 1 comment · 18 days ago

kevin M. benard — That's awesome because we've already got a treatment for Eczema that works. If you read ...

DISQUS



PRESS RELEASES

- SANOFI APPOINTS MUZAMMIL MANSURI TO EXECUTIVE COMMITTEE AND EXECUTIVE VICE PRESIDENT, STRATEGY & BUSINESS DEVELOPMENT
- LifeWatch™ Receives FDA Clearance for Its Continuous Vital Signs Monitoring Service

FEATURED JOBS

- Senior/Principal Quality Product Leader, Small Molecules - South San Francisco, CA (- 94080)
- Senior Counsel/Associate General Counsel - Berkeley
- Research Scientist-Regulatory Affairs Medical Devices - Indianapolis, IN

